Our interest in miRNAs began with a desire to solve the fundamental question of how organs form at the right time during development [1, 4], and this core theme has since led us to a broader interest in the role of miRNAs in human disease and aging [5, 6]. We initially focused on using C. elegans to ﬁnd conserved genes and molecules that control developmental timing and to understand the underlying mechanisms utilized, but more recently we have focused on translating this information to the analysis of more complex organisms. For example, since many of the C. elegans developmental timing genes are related to human cancer genes, we have moved to mammals to examine the role of their homologues in controlling timing of cell diﬀerentiation and disease. In one example, let-7, a founding member of the miRNA family, is known to control essential development processes in stem cells such as cellular diﬀerentiation, in large part through our work [2, 7, 8]. In humans, we have shown that miRNAs are key cancer genes (see below), and administration of tumor-suppressor miRNAs to mice with cancer causes dramatic tumor regression.
We demonstrated for the ﬁrst time that a miRNA directly binds its target mRNA in vivo and described the minimal sequences necessary for miRNA control of target sequences [9, 10]. We used this information to design one of the ﬁrst bioinformatics screens to identify novel miRNA targets in an eﬀort to understand how these miRNAs control diﬀerentiation [3, 11]. Most of the dozen or so targets we identiﬁed encode transcription factors, leading to our assertion that these miRNAs are master temporal control genes. Another target of let-7 was the C. elegans homologue of the human proto-oncogene RAS (see below), which proved to be a conserved interaction in human cells . This led to our intense analysis of roles for miRNAs in cancer pathways, in both human cells and in mouse models (see below).
Future work: We have taken an in-depth approach to investigating all aspects of the lin-4 and let-7 miRNAs as models for miRNA biology, leading to these miRNAs being the best understood of any miRNAs and we will continue to dig deeply into these models. Speciﬁcally, we are interested in what regulates these miRNAs, where and when are they expressed, what their roles are, what their targets are, what pathways they function in and the extent of their reach in C. elegans and mammals. We showed that both the lin-4 and let-7 RNAs are transcriptionally regulated  and begin to be expressed at critical times in development. We have dissected the promoter regions of lin-4 and let-7 and have identiﬁed temporal control elements that bind to proteins, which we are pursuing . let-7 is regulated by LIN-28 protein in many animals and we have undertaken an unbiased screen for LIN-28 binding sites in RNAs. Our data shows that LIN-28 regulates many genes, including let-7. These are high priority for further study, especially since LIN-28 is a key stemness gene in C. elegans and mammals .
We conducted a genome-wide RNAi screen for suppressors of the lin-4 and let-7 miRNA mutants. We identiﬁed around 50 genes that can suppress the lethality of a let-7 mutant [11, 14]. These include important transcription factors; signal transduction molecules; RNA metabolism genes; and other genes with unknown functions but for which there are human disease homologues, like apl-1/APP. Given the lack of functional information about APP, a key gene in Alzheimer’s disease, we are investigating apl-1 in detail. We found that apl-1 acts in our developmental timing pathway, and its expression is temporally regulated late in development by heterochronic genes and miRNAs, like let-7 . This work provides insights into the age-related increase in APP expression in Alzheimer’s disease. It also pointed to human APP as a target of miRNAs, and that these miRNAs may be potential Alzheimer’s therapeutics. This work also demonstrates the close relationship between developmental timing, aging and disease, an emerging ﬁeld of which we are at the forefront.
As part of the modENCODE project we have used next-generation sequencing to identify hundreds of novel, temporally expressed miRNAs during development in C. elegans [16-18], most of which remain of unknown function. In addition to the lin-4 and let-7 families, recent studies have shown that another ﬁve out of thirty-one temporally regulated miRNAs in C. elegans possess mammalian miRNA homologues. Therefore, this group of potentially important, highly conserved miRNAs is being analyzed in my lab for informative expression patterns and phenotypes during development. The hypotheses we are testing are that conserved, temporally expressed miRNAs will be essential for proper growth and development in C. elegans. For example, we have found that mir-34, a homologue of a human tumor-suppressor miRNA activated by p53 , is temporally expressed in the vulva and plays a role in the radiation-sensitivity of these cells . This observation was the ﬁrst in vivo phenotype for this important miRNA. We also hypothesize that their homologs will play important roles during mouse development. Further, as part of this analysis we developed a protocol for in situ hybridization of mammalian miRNAs that is now standard in the ﬁeld (). Thus, I expect our “discovery” work in C. elegans will continue to inform studies in more complex organisms.
- Banerjee, D. and F. Slack, Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression. Bioessays, 2002. 24(2): p. 119-29.
- Boehm, M. and F. Slack, A developmental timing microRNA and its target regulate life span in C. elegans. Science, 2005. 310(5756): p. 1954-7.
- Johnson, S.M., et al., RAS is regulated by the let-7 microRNA family. Cell, 2005. 120(5): p. 635-47.
- Slack, F. and G. Ruvkun, Temporal pattern formation by heterochronic genes. Annu Rev Genet, 1997. 31: p. 611-34.
- Boehm, M. and F.J. Slack, MicroRNA control of lifespan and metabolism. Cell Cycle, 2006. 5(8): p. 837-40.
- Esquela-Kerscher, A. and F.J. Slack, Oncomirs: microRNAs with a role in cancer. Nature Reviews Cancer, 2006. 6: p. 259-269.
- Reinhart, B., et al., The 21 nucleotide let-7 RNA regulates C. elegans developmental timing. Nature, 2000. 403: p. 901-906.
- Slack, F.J., et al., The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the lin-29 transcription factor. Molec. Cell, 2000. 5: p. 659-669.
- Vella, M.C., et al., The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3’UTR. Genes Dev, 2004. 18(2): p. 132-7.
- Vella, M.C., K. Reinert, and F.J. Slack, Architecture of a validated microRNA::target interaction. Chem Biol, 2004. 11(12): p. 1619-23.
- Grosshans, H., et al., The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Dev Cell, 2005. 8(3): p. 321-30.
- Johnson, S.M., S.Y. Lin, and F.J. Slack, The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Dev Biol, 2003. 259(2): p. 364-79.
- Nimmo, R.A. and F.J. Slack, An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma, 2009. 118(4): p. 405-18.
- Ding, X.C., F.J. Slack, and H. Grosshans, The let-7 microRNA interfaces extensively with the translation machinery to regulate cell diﬀerentiation. Cell Cycle, 2008. 7(19): p. 3083-90.
- Niwa, R., et al., The expression of the Alzheimer’s amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in Caenorhabditis elegans. Dev Biol, 2008. 315(2): p. 418-25.
- Gerstein, M.B., et al., Integrative analysis of the Caenorhabditis elegans genome by the modENCODE project. Science, 2010. 330(6012): p. 1775-87.
- Kato, M., et al., Age-associated changes in expression of small, noncoding RNAs, including microRNAs, in C. elegans. RNA, 2011. 17(10): p. 1804-20.
- Kato, M., et al., Dynamic expression of small non-coding RNAs, including novel microRNAs and piRNAs/21U-RNAs, during Caenorhabditis elegans development. Genome Biol, 2009. 10(5): p. R54.
- He, L., et al., A microRNA component of the p53 tumour suppressor network. Nature, 2007.
- Kato, M., et al., The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene, 2009. 28(25): p. 2419-24.
- Johnson, C.D., et al., The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells. Cancer Res, 2007. 67(16): p. 7713-22.